What does the evidence show about Luteolin's effects?

Read Off Label rates the evidence for Luteolin as Preclinical and the benefit magnitude as low, producing an overall grade of C (4.8/10). Frequently cited alongside fisetin and quercetin in the senolytic-stack literature but with much thinner human data than either.

What safety findings are reported for Luteolin?

Luteolin has a low risk profile in the database. Low (poor oral bioavailability is the main practical limit; theoretical CYP1A2/3A4 interactions at high doses) Legal status: OTC.

What doses or routes are reported for Luteolin?

100-300 mg/day; often combined with quercetin/apigenin for senolytic stacks; food sources include parsley, celery, artichoke This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.

Rankings / Longevity — Senolytics & Polyphenols

Luteolin

Longevity · Flavonoid (senolytic-adjacent)

Tier C

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

senolyticanti-inflammatoryotc

4.8 / 10

Tier C

Ev 2 Bn 2 Sf 9

Bottom line

Read Off Label grades Luteolin as C (4.8/10) based on preclinical evidence, low benefit magnitude, and a low-risk safety profile.

Frequently cited alongside fisetin and quercetin in the senolytic-stack literature but with much thinner human data than either.

Studied, labeled, or reported-use context: 100-300 mg/day; often combined with quercetin/apigenin for senolytic stacks; food sources include… — OTC; not individualized guidance.

What the evidence says

Frequently cited alongside fisetin and quercetin in the senolytic-stack literature but with much thinner human data than either. Preclinical evidence overlaps with D+Q-style pathways; standalone clinical outcome evidence is absent. Bioavailability is poor — liposomal/phytosomal formulations help.

Mechanism

3',4',5,7-tetrahydroxyflavone; PI3K/AKT/mTOR inhibition; NF-kB suppression; tested as a senolytic adjunct to dasatinib + quercetin; mast-cell stabilizer; weak MAO-B inhibitor

Studied, labeled, or reported dose & route

100-300 mg/day; often combined with quercetin/apigenin for senolytic stacks; food sources include parsley, celery, artichoke

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Luteolin's effects?: Read Off Label rates the evidence for Luteolin as Preclinical and the benefit magnitude as low, producing an overall grade of C (4.8/10). Frequently cited alongside fisetin and quercetin in the senolytic-stack literature but with much thinner human data than either.
What safety findings are reported for Luteolin?: Luteolin has a low risk profile in the database. Low (poor oral bioavailability is the main practical limit; theoretical CYP1A2/3A4 interactions at high doses) Legal status: OTC.
What doses or routes are reported for Luteolin?: 100-300 mg/day; often combined with quercetin/apigenin for senolytic stacks; food sources include parsley, celery, artichoke This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Luteolin work?: 3',4',5,7-tetrahydroxyflavone; PI3K/AKT/mTOR inhibition; NF-kB suppression; tested as a senolytic adjunct to dasatinib + quercetin; mast-cell stabilizer; weak MAO-B inhibitor

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.